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Impaired Memory and Evidence of Histopathology in CA1 
Pyramidal Neurons through Injection of Aβ1-42 Peptides 
into the Frontal Cortices of Rat 
Introduction: Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders, 
which has much benefited from animal models to find the basics of its pathophysiology. In our 
previous work (Haghani, Shabani, Javan, Motamedi, & Janahmadi, 2012), a non-transgenic 
rat model of AD was used in electrophysiological studies. However, we did not investigate the 
histological aspects in the mentioned study. 
Methods: An AD model was developed through bilateral injection of amyloid-β peptides (Aβ) 
into the frontal cortices. Behavioral and histological methods were used to assess alterations in 
the memory and (ultra)structures. Furthermore, melatonin has been administered to assess its 
efficacy on this AD model.
Results: Passive avoidance showed a progressive decline in the memory following Aβ injection. 
Furthermore, Nissl staining showed that Aβ neurotoxicity caused shrinkage of the CA1 pyramidal 
neurons. Neurodegeneration was clearly evident from Fluoro-jade labeled neurons in Aβ treated 
rats. Moreover, higher NF-κB immunoreactive CA1 pyramidal neurons were remarkably 
observed in Aβ treated rats. Ultrastructural analysis using electron microscopy also showed the 
evidence of subcellular abnormalities. Melatonin treatment in this model of AD prevented Aβ-
induced increased NF-κB from immunoreaction and neurodegeneration.  
Discussion: This study suggests that injection of Aβ into the frontal cortices results in the memory 
decline and histochemical disturbances in CA1 pyramidal neurons. Furthermore, melatonin can 
prevent several histological changes induced by Aβ.
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1. Introduction
lzheimer’s disease (AD) is one of the most 
prevalent neurodegenerative disorders. One 
of the main hypotheses about the pathol-
ogy of AD is amyloid-β (Aβ) aggregations, 
which is known to be a basis for the majority of structural 
and functional changes in the vulnerable loci of the brain, 
including frontal cortex areas, entorhinal cortex, and the 
hippocampus (Huang & Muck, 2012).
The pathological signs of AD in human include the ap-
pearance of Aβ aggregation firstly in frontal cortex areas 
and over time its spread to the subcortical structures in a 
frontotemporal fashion (Arriagada, Growdon, Hedley-
Whyte, & Hyman, 1992; Harris et al., 2010; Nath et al, 
A
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2012). We exploited this point of view in a rat model of 
AD to study electrophysiological properties of CA1 py-
ramidal neurons and the cellular basis of Aβ-induced 
changes in the neuronal intrinsic excitability (Haghani, 
Shabani, Javan, Motamedi, & Janahmadi, 2012; Haghani, 
Janahmadi, & Shabani, 2012; Esmaeili Tazangi, Moosavi, 
Shabani, & Haghani, 2015). To develop this model, Aβ 
(1-42) peptides were deeply injected into the frontal corti-
ces bilaterally. However, histological aspects of this model 
were not investigated.   
The usage of melatonin has a long history in the preven-
tion of age- and AD-dependent cognitive declines. Data 
from clinical trials indicated that melatonin supplementa-
tion improves sleep, ameliorates sundowning and slows 
down the progression of cognitive impairment in patients 
with AD (Wang & Wang, 2006; Rosales-Corral et al., 
2012). Furthermore, although it has long been shown that 
melatonin efficiently protects the neuronal cells from Aβ-
mediated toxicity via antioxidant and anti-amyloid prop-
erties (Cheng, Feng, Zhang, & Zhang, 2006), therapeutic 
effects of melatonin are still under intense research (Jun et 
al., 2013; Liu et al., 2013; Rudnitskaya et al., 2015; Ste-
fanova et al., 2015). In this regard, injection of Aβ pep-
tides into frontal cortex was used as a less clarified cause 
in the early onset and in vivo model of AD. Also, we were 
prompted to further investigate the effectiveness of mela-
tonin treatment on the potential behavioral changes and 
histological alterations in the hippocampus. 
Present study was done to address some of the histo-
logical consequences of toxicity in the hippocampus 
induced by frontal cortex injection of Aβ peptides and 
to further examine the effectiveness of melatonin treat-
ment against these potentially Aβ-induced cognitive 
and histologic alterations. We showed that remotely in-
jected Aβ peptides did exert memory decline and had 
detrimental histochemical effects in the most vulnerable 
cells of the hippocampus, i.e. CA1 pyramidal neurons. 
Additionally, melatonin treatment prevented some of 
the Aβ-induced histopathologies. 
2. Methods
2.1. Animals
Male Wistar rats (7-8 weeks old) weighting 100-120 g 
were kept in a 12:12 h light-dark cycle (lights on at 6 
a.m.) and humidity-controlled animal house with water 
and food ad libitum. The experiments were conducted 
in accordance with the animal care and guidelines ap-
proved by the Institutional Ethic Committees at Iran 
University of Medical Sciences and Shefa Neuroscience 
Research Center. Rats were divided into four groups in-
cluding, control, sham (in which normal saline 3µL was 
injected into the frontal cortex bilaterally), Aβ injected, 
and Aβ injected plus melatonin treatment. The number 
of animals used in each experiment will be appropriately 
mentioned in the results. 
2.2. Animal surgery and melatonin treatment
Aβ (1-42, Sigma, UK) was dissolved in the normal sa-
line at a concentration of 10 ng/µL, aliquoted and stored at 
-80°C until use. For animal surgery, rats were anesthetized 
intraperitoneally (i.p.) with a mixture of ketamine (80 mg/
kg) and xylazine (20 mg/kg). 3µL of prepared Aβ was 
bilaterally injected into the frontal cortex using a 10-µL 
Hamilton syringe and stereotaxic apparatus (Bregma co-
ordinates: 3.2 mm anteroposterior, 2 mm mediolateral, and 
3mm depth) according to the literature (Haghani, Shabani, 
Javan, Motamedi, & Janahmadi, 2012; Altobellia, Cimini, 
Espositoc, Iuvonec, & Ciminia, 2015). Sham-vehicle rats 
underwent the same surgical procedure, except that nor-
mal saline (as a vehicle of Aβ peptide) was bilaterally in-
jected. A separate group of Aβ treated rats received daily 
i.p. injection of melatonin 30 mg/kg for 10 days starting 
from the day of surgery. The histochemical experiments 
were conducted 10 days after Aβ injection.
2.3. Passive avoidance behavioral test
Behavioral assessment in rats was evaluated using a 
passive avoidance shuttle box (Haghani, Shabani, Javan, 
Motamedi, & Janahmadi, 2012). Briefly, on the third day 
after Aβ injection, rats were subjected to the adaptation 
and learning sessions. To do this, rats were individually 
put into the light chamber and allowed to circulate freely 
in the shuttle box. During 60 s of adaptation, if the rat did 
not enter into the dark chamber, it was excluded from the 
rest of experiments. Two hours after adaptation, the learn-
ing task was done in which the rats were again individu-
ally placed into the light chamber and after 10 s the door 
between the chambers was lifted. Once the rat entered 
into the dark chamber an electrical foot shock (1 mA, 50 
Hz square wave, 1.5 s) was applied. After 20 s, rats were 
removed from the dark chamber. This learning task was 
repeated every 2 min until the rats learnt not to enter the 
dark chamber during a 300 s period. The first and second 
retention sessions were conducted one day and one week 
later, respectively. In the learning and retention trials the 
latency of rats to enter the dark chamber via open door 
was considered as Step Through Latency (STL) and the 
maximum cutoff time for the STL was 300 s.
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2.4. Histological assessments
2.4.1. Nissl staining. 
After the second retention session, the rats were deeply 
anesthetized with ether and sacrificed. Brains have been 
fixed via transcardial perfusion of phosphate buffered sa-
line (PBS, 0.1 M, pH 7.4) followed by 200-250 mL para-
formaldehyde solution (1%) (Saffarzadeh et al., 2015). 
Brains were removed and postfixed by fixative for one 
week at 4°C. Then, brains were dehydrated using a series 
of alcohols and xylene. 
Finally, the paraffin embedded blocks were prepared. 
The blocks were cut coronally on a microtome at a thick-
ness of 8 µm and mounted onto the silan-coated slides. 
Before staining, the sections on the glass slides were depa-
raffinized and then hydrated using a series of alcohols and 
distilled water, and finally stained using Cresyl violet for 
general histology. The soma diameter (in µm) of pyrami-
dal neurons was assessed from the photos taken from CA1 
pyramidal layer under 40X light microscopy. To quantify 
the soma diameters, a pyramidal-like neuron was random-
ly selected from pyramidal layer of the CA1 region from 
each slice and an average was taken from each neuron’s 
long, short, and an intersected oblique axes defined on its 
soma using Image J software by an experimenter blind to 
the experimental groups.
2.4.2. Fluoro-jade staining
 Degenerating neuronal soma and their processes were 
detected using Fluoro-Jade B (Abcam, UK). Briefly, brain 
sections were deparaffinized on a 60ºC heater for 20 min 
and incubated in each of the following solutions for the 
time indicated: alcohol 100%, 3 min; alcohol 70%, 1 min; 
distilled water (H2O), 1 min; potassium permanganate 
0.06%, 15 min; H2O, 1 min; Fluoro-Jade B 0.001% in 
acetic acid 0.09%, 30 min; H2O, 2×1 min. Stained sec-
tions were allowed to dry at room temperature protected 
from the light. Sections were coverslipped and kept at 
4ºC avoided from the light (Schmued, Albertson, & Slik-
ker, 1997). Then, they were examined using an inverted 
microscope (BX71, Olympus, Japan) equipped with the 
fluorescence filter. The pictures were captured by a digital 
camera. The number of green fluorescently labeled neu-
rons per mm2 in CA1 pyramidal layer was counted from 
3-4 sections per brain using Image J software.
2.4.3. NF-κB immunohistochemistry
After deparaffinization and rehydration using alco-
hol and H2O, the endogenous peroxidase activity was 
quenched by hydrogen peroxide 0.3% diluted in PBS 
(0.1 M, pH 7.4) for 10 min. After washing in PBS, sec-
tions were brought to a boil in 10 mM sodium citrate 
buffer (pH 6) for 10 min. After cooling and washing in 
PBS, sections were blocked with normal goat serum di-
luted in PBS for 20 min. Active NF-kB was probed by 
using an anti-p65 antibody, Biotinylated Goat Anti-Rat 
IgG (BA-9400, Vector Lab, Canada) diluted 1:50 in PBS 
at 4ºC overnight. After washing, sections were incubat-
ed with VECTASTAIN Elite ABC reagents (PK-6100, 
Vector Lab, Canada) for 40 min at room temperature to 
visualize the binding of the antibody to p65. The chro-
mogen diaminobenzidine tetrahydrochloride (DAB, 
Sigma) was used followed by the counterstaining with 
Hematoxylin. The pictures were captured by a digital 
camera. The number of immunoreactive brownish neu-
rons per mm2 in CA1 pyramidal layer was counted from 
3-4 sections per brain using Image J software (Butler, 
Moynagh, & O’Connor, 2002).
2.4.4. Ultrastructural analysis
The deeply anesthetized rats were transcardially per-
fused with 200 mL of normal saline followed by 200 
mL of paraformaldehyde 4% in PBS (0.1 M, pH 7.4) at 
4°C. The hippocampi were removed and immersed in 
glutaraldehyde 2.5%. The specimens were then washed 
in PBS and postfixed in OsO4 1% for 2 h at room tem-
perature. 
After dehydration in ascending ethanols, they were 
embedded in Epon 812 resin (TAAB, UK) and polymer-
ized for 48 h at 55°C. Semi-thin sections (0.3 μm) were 
stained with toluidine blue to identify CA1 pyramidal 
layer. Subsequently, 70 nm sections were cut and stained 
with uranyl acetate and lead. The sections were exam-
ined with a LEO 906 electron microscope (Zeiss, Ger-
many). Ultrathin sections were analyzed to find changes 
in neuronal ultrastructure consistent with apoptosis, 
including swelling and vacuolization of mitochondria, 
nuclear pyknosis, and margination of nucleoli (Kerma-
nian et al., 2012).
2.5. Statistical analyses
Statistical analysis was performed with SPSS software 
(version 17). Analysis with one-sample Kolmogorov-
Smirnov showed that the distribution of data was normal. 
Therefore, the parametric test, One-way ANOVA was 
used followed by Tukey post-hoc test for all statistical 
comparisons. The values are presented as mean±S.E.M. 
P<0.05 was statistically considered significant.
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3. Results
3.1. Bilateral Aβ injection into the frontal cortex 
caused memory impairment
On the third day after Aβ injection, rats were subjected 
to the adaptation and learning sessions. During learning 
sessions, rats learnt not to enter dark chamber during 300 
s after giving electrical foot shocks. The number of foot 
shocks was considered as a measure of learning ability 
(control 1.2±0.1, n=10; sham 1.2±0.1, n=7; Aβ-treated 
1.3±0.15, n=10; Aβ+Melatonin treated 1.23±0.09, n=11; 
P=0.91 (Figure 1A). 
The first retention trial was assessed 1 day after lean-
ing session, indicative of a short-term memory function, 
via measuring Step Through Latency (STL) to enter dark 
chamber. In intact rats, this latency was 279±14 s (n=10) 
and injection of 3 µL normal saline in each frontal cortex 
(sham rats) did not change this latency (265±20 s, n=7; 
P=0.52), while Aβ treatment significantly reduced the STL 
in the first retention trial compared to that of control rats 
(164±35 s, n=10, P=0.019; Figure 1B). 
To have an estimate of a longer term memory function, 
probe test was measured 1 week after the first retention 
trial. At this time point, there was also no difference in 
the ability of rats in the passive avoidance task between 
control and sham groups (Control, 194±30 s, n=10; Sham, 
220±20 s, n=7; P=0.76). However, STL was severely re-
duced in Aβ treated rats compared to control rats (86±31 
s, n=10; P=0.001; Figure 1C). 
Evaluating the effectiveness of melatonin therapy, how-
ever, showed that melatonin did not prevent Aβ-induced 
memory deficit neither in the first nor in the second reten-
tion trials (149±26 s, n=11, P=0.45 and 113±26 s, n=11, 
P=0.94, respectively; Figure 1B & C). These findings 
imply that injection of Aβ into deep frontal cortices can 
aggravate hippocampal dependent memory to an extent 
that even pharmacologically relevant dose of melatonin 
cannot prevent it.
3.2. Injection of Aβ peptide into the frontal cortex re-
duced the soma diameter of CA1 pyramidal neurons
Histological evaluation with Nissl staining 10 days after 
Aβ injections showed that the diameter of CA1 pyrami-
dal soma did not change in sham operated rats (control 
16.5±0.5 µm, n=12 slices from 4 rats; sham 17.1±0.4 µm, 
n=10 slices from 4 rats; P=0.91; Figure 2A-B, & E). How-
ever, after 10 days of Aβ peptide injection into the frontal 
cortex, the soma diameter of pyramidal neurons was sig-
nificantly reduced compared to control rats (12.6±0.6 µm, 
n=14 slices from 5 rats; P=0.002; Figure 2C & E). 
Moreover, melatonin treatment had no effect compared 
to Aβ treated rats (11.9±0.5 µm, n=11 slices from 3 rats, 
P=0.45; Figure 2D & E). These findings indicate that the 
injection of Aβ peptides into the frontal cortices reduces 
soma diameter of CA1 pyramidal neurons. However, 
melatonin treatment could not prevent this effect of Aβ 
peptides.
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Figure 1. Injection of Aβ into the frontal cortices impaired 
memory. A) Leaning trial on the third day after Aβ injection 
as indicated by the number of shocks to learn not to enter the 
dark chamber during 300s period. B) The first retention trial, 
24 h after learning trial and C) The second retention trial one 
week after the first retention trial. *P=0.019 and ***P=0.001 
compared to control group. Analysis was done by one-way 
ANOVA with Turkey post-hoc test.
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3.3. Injection of Aβ peptides into the frontal cortex 
increased degeneration of CA1 pyramidal neurons
Cellular degeneration is one of the hallmarks of neu-
rodegenerative disorders like AD. To address this issue 
in the present animal model of AD, neurodegenera-
tion was assessed using a highly sensitive fluorescent 
dye, Fluoro-jade B. Analysis of the images from con-
trol and sham operated rats showed a few fluorescent 
neurons (per mm2) in the CA1 pyramidal layer (con-
trol 2.8±0.4 neurons, n=8 slices from 2 rats and sham 
3.1±0.8 neurons, n=9 slices from 3 rats, P=0.95; Fig-
ure 3A-C). Interestingly, the tissues from Aβ treated 
rats compared to control rats showed more abundant 
fluorescent neurons in CA1 pyramidal layer (26.4±0.8 
neurons, n=10 slices from 3 rats, P<0.001; Figure 3D 
& F). In spite of a significant reduction in the num-
ber of degenerating neurons by 10 days treatment with 
melatonin (12.9±1.2 neurons, n=12 slices from 3 rats; 
P=0.005, Figure 3E & G), this reduction did not reach 
the control levels.
3.4. Injection of Aβ peptides into the frontal cortex 
increased NF-κB immunoreactivity in CA1 pyra-
midal neurons
 NF-κB is one of the main signaling molecules activated 
and participated in the physiological and pathophysiologi-
cal phenomena, including inflammation. Upon activation, 
this complex molecule translocates from the cytoplasm 
Figure 2. Injection of Aβ into the frontal cortices reduced the soma size. Photomi-
crographs of Nissl staining of CA1 pyramidal neurons in control (A), sham (B), Aβ 
treated (C), and Aβ+melatonin treated rats (D). Shrunk and darkly stained pyra-
midal neurons are remarkable in C and D. Quantitative analysis of soma diameter 
between groups (E). **P=0.002 indicates comparison with control rats. Analysis was 
done by one-way ANOVA with Turkey post-hoc test. Scale bar shows 50 µm.
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to the nucleus to alter gene transcription. In this regard, 
we measured the number of immunoreactive CA1 pyra-
midal neurons (per mm2) in our AD model. There were 
not differences between control and sham operated rats 
(6.14±0.4 neurons, n=10 slices from 3 rats; 7.1±0.8 neu-
rons, n=12 slices from 3 rats, respectively; P=0.48; Figure 
4A & B); however, in Aβ treated rats compared to con-
trols, there was an evidence of enhanced NF-κB immuno-
reaction in the CA1 pyramidal neurons (21±0.8 neurons, 
n=13 slices from 4 rats, P<0.001; Figure 4C). Ten days of 
melatonin treatment decreased Aβ-enhanced NF-κB im-
munoreactivity in these neurons (15.8±0.4 neurons, n=10 
slices from 4 rats; P=0.003, Figure 4D & E).
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Figure 3. Injection of Aβ into frontal cortices induced neurodegeneration. Fluoro-jade photomicrographs of the whole hip-
pocampus (A), CA1 pyramidal neurons of control (B), sham (C), Aβ treated (D), and Aβ+melatonin treated rats (E). Higher 
resolution image of fluorescent neurons from an Aβ treated rat (F). Arrows show degenerating fluorescent neurons. Scale 
bars show 50 µm for B-E and 20 µm for F. G) Quantitative analysis of the number of fluorescent neurons in different groups. 
***P<0.001 and ‡‡P=0.005 indicate comparisons with control and Aβ groups, respectively. Analysis was done by one-way 
ANOVA with Turkey post-hoc test.
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3.5. Injection of Aβ peptides into the frontal cortex 
induced ultra-structural changes in CA1 pyrami-
dal neurons
Ultrastructural assessment using electron microscopy 
showed that in the control and sham operated rats, CA1 
pyramidal neurons had oval nuclei with evenly dispersed 
chromatin and clear nucleoli in the center of nucleus 
(Figure 5A & B). Furthermore, both plasmalemma and 
nucleolemma were intact in neurons obtained from con-
trol and sham rats. In contrast, the CA1 pyramidal neu-
rons from Aβ- and Aβ+mel atonin-treated rats showed the 
criteria similar to apoptotic neurons, in which degenerated 
neurons are evident in CA1 pyramidal layer, with nucleo-
lemma invaginations implying the shrinkage of the nuclei 
and/or nuclear lysis, and chromatin aggregation (Figure 
5C & D). Our results from electron microscopic study im-
ply that injection of Aβ peptides into the frontal cortex can 
exert ultrastructural changes similar to the characteristics 
of apoptosis in the hippocampal neurons.
4. Discussion
In the present rat model of AD developed by injection of 
Aβ (1-42) peptide solution into the frontal cortical areas, 
behavioral changes and histochemical alterations were 
assessed in the most vulnerable hippocampal neurons in 
AD. Passive avoidance test showed a progressive decline 
in the memory, which is a behavior strongly dependent 
on the normal hippocampal function. Histological evalu-
Figure 4. Injection of Aβ into the frontal cortices increased NF-κB positive pyrami-
dal neurons. Photomicrographs of NF-κB immunohistochemistry in CA1 pyramidal 
neurons in control (A), sham (B), Aβ treated (C), and Aβ+melatonin treated rats (D). 
***P<0.001 and ‡‡P=0.003 comparisons with control and Aβ groups, respectively (E). 
Analysis was done by one-way ANOVA with Turkey post-hoc test. Scale bar shows 
50 µm.
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ations also verified evidence of alterations in the structure 
and biochemical properties of CA1 pyramidal neurons. 
Furthermore, daily treatment with melatonin was effective 
to prevent several histological disturbances, but not mem-
ory decline induced by Aβ injection into frontal cortices.
Postmortem studies show that Aβ aggregation in patients 
with AD firstly appears in the frontal cortex areas and then 
spreads out over time to the subcortical structures, includ-
ing hippocampus (Arriagada, Growdon, Hedley-Whyte, 
& Hyman, 1992; Harris et al., 2010; Nath et al., 2012). 
Recently, we have benefited from this view in an in vivo 
rat model of AD to study electrophysiological properties 
and the cellular basis of excitability in CA1 pyramidal 
neurons (Haghani, Shabani, Javan, Motamedi, & Janah-
madi, 2012; Haghani, Janahmadi, & Shabani, 2012). To 
develop this AD model, Aβ peptides have been injected 
deeply into the frontal cortices bilaterally. This model has 
advantages of rapidly developing and early onset of cogni-
tive symptoms of AD (as we evaluated just 3 days after Aβ 
injection), including impairment in the passive avoidance 
memory. Genetic mice models of AD are mostly reported 
to show memory impairments after at least 4 months after 
birth (Kaczorowski, Sametsky, Shah, Vassar, & Dister-
hoft, 2011; Stevens & Brown, 2014; Cañete, Blázquez, 
Tobeña, Giménez-Llort, & Fernández-Teruel, 2014). 
Moreover, non-transgenic rat model of AD, used in the 
present study, has functional alterations at the cellular 
level as evidenced by altered intrinsic electrical properties 
in the hippocampal neurons (Haghani, Shabani, Javan, 
Motamedi, & Janahmadi, 2012; Haghani, Janahmadi, & 
Shabani, 2012) and impaired induction of plasticity via 
decreased probability of neurotransmitter release (Es-
maeili Tazangi, Moosavi, Shabani, & Haghani, 2015). 
Therefore, structural and functional alterations seen in the 
hippocampal neurons undoubtedly could be attributed to 
the neurodegeneration induced by either a remote injury 
(due to the method of injection), and/or injected Aβ pep-
tides. However, several questions have remained to ad-
dress about histological properties and effectiveness of a 
conventional treatment, i.e. using melatonin in this model. 
Impaired cognition and memory decline are the earliest 
symptoms of developing AD in humans. In this study, we 
assessed memory function of rats using passive avoid-
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Figure 5. Injection of Aβ into the frontal cortices induced ultra-structural changes in CA1 pyra-
midal neurons. Electron microscopic photomicrographs from CA1 pyramidal neurons of control 
(A) and sham rats (B), in which arrows show oval nuclei with evenly dispersed chromatin and 
clear nucleoli in the center of nucleus. Electron microscopic photomicrographs from CA1 pyrami-
dal neurons of Aβ (C) and Aβ+melatonin (D) treated rats, respectively, in which arrows indicate 
nucleolemma invaginations and chromatin aggregation.
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ance test. The reliability and validity of this test have been 
demonstrated by numerous studies to assess the ability of 
cognitive function in rodents (Filali et al., 2012; Webster, 
Bachstetter, Nelson, Schmitt, & Van Eldik, 2014). Like-
wise, we also found a progressive deteriorating effect of 
Aβ on the memory function of rats.
Hippocampus, in the temporal lobe is one of the main 
targets of AD pathophysiology. Decreased hippocampal 
volume due to neuronal shrinkage and loss through an ac-
celerated apoptosis in AD is detectable using imaging and 
pathological studies. In the present study, Nissl staining 
showed evidence of shrinkage in the CA1 pyramidal neu-
rons, but not neuronal loss (data not shown). Shrinkage 
and neuronal loss have been reported in both animal mod-
els of AD (Bondolfi et al., 2002; Li et al., 2013; Zhang, 
Dong, Zhao, & Ma, 2014) and clinical studies (Simić, 
Kostović, Winblad, & Bogdanović, 1997; Zarow et al., 
2005). It is worthy to note that the imaging studies im-
plied that structural changes in the hippocampal CA1 area 
might be the underpinning of cognitive dysfunctions in 
AD (Lim et al., 2012). 
Moreover, labeling with fluorescent dye, Fluoro-jade, 
approved activation of neurodegenerative processes in 
CA1 pyramidal neurons induced by Aβ injection into the 
frontal cortices, consistent with other studies showing in-
creased number of degenerating neurons in AD animal 
models (Damjanac et al., 2007; Kemppainen, Hämäläin-
en, Miettinen, Koistinaho, & Tanila, 2014). Furthermore, 
consistent with findings using light microscopy, our study 
with electron microscopy showed ultra-structural evidence 
of apoptosis in CA1 pyramidal neurons of Aβ-treated 
rats. These findings are in line with other studies indicat-
ing detrimental effects of Aβ peptides on the subcellular 
structures in the hippocampal and cortical neurons (Li et 
al., 2012; Balietti et al., 2013). Our further investigation 
using staining with Congo red, to find amyloid plaques, 
however, did not indicate the formation of plaques in the 
CA1 region ten days after Aβ injection (data not shown).
Inflammation as one of the important features of AD in 
this study has been brought under scrutiny using histo-
chemical measurement of NF-κB positive pyramidal neu-
rons in CA1 pyramidal layer. NF-κB is a protein complex 
located in the vicinity of postsynaptic machinery and cy-
toplasm, which activates through physiological synaptic 
stimulations and during inflammatory processes (Butler, 
Moynagh, & O’Connor, 2002; Meffert, Chang, Wiltgen, 
Fanselow, & Baltimore, 2003). In this study, Aβ injection 
into the frontal cortices increased the number of NF-κB 
immunoreactive neurons, consistent with other studies in 
animal models of AD (Liu et al., 2007; Kim et al., 2009; 
He et al., 2011; Wu et al., 2011; Fakhfouri et al., 2012) and 
postmortem studies from patients with AD (Terai, Mat-
suo, & McGeer, 1996; Yoshiyama, Arai, & Hattori, 2001).
Since different etiologies have been attributed to AD, 
therapies aimed at completely preventing or curing AD 
remained immature and current therapeutics are only able 
to slow down its progression. Anti-oxidative and anti-
amyloid properties of melatonin have been extensively 
studied (Cheng, Feng, Zhang, & Zhang, 2006; Rosales-
Corral et al., 2012). A vast majority of studies used sys-
temic treatment with melatonin, ranging 10-50 mg/kg/
day, and demonstrated its neuroprotective effects in dif-
ferent animal models of AD (Wang, Ling, Cao, Zhu, & 
Wang, 2004; Feng et al., 2004; Yang et al., 2011). In the 
present study, treatment with melatonin (30 mg/kg/day) 
did not prevent or alleviate Aβ-induced memory decline, 
or decrease in soma diameter, and ultrastructural altera-
tions. There are other evidence that melatonin treatment 
also fails to prevent amyloid burden and oxidative damage 
in Tg2576 model of AD in mice (Quinn et al., 2005). 
However, we showed that melatonin prevented to a con-
siderable extent an enhanced NF-κB immunoreactivity 
and neurodegeneration, indicating of its effectiveness to 
inhibit inflammatory pathways triggered by the intrafron-
tal cortex injection of Aβ.
In this study, we showed that the injection of Aβ into the 
frontal cortices impaired memory and resulted in the cel-
lular features of AD in the hippocampus within 10 days. 
This experimental model of AD, besides its simplicity (to 
be developed in vivo), due to early onset of behavioral and 
histological manifestations of AD, may have an advantage 
for the electrophysiological and histological studies to as-
sess Aβ induced neurotoxicity in a frontotemporal fash-
ion, similar to that occurs naturally in patients with AD.
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